ROBERT SCHUSTER: Open Payments
NPI 1871525931 · DADEVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,683 in 123 payments from 16 companies in 2025. Trend: 2023 $1,986 · 2024 $2,211 · 2025 $2,683
Food & beverage: $2,683
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $609 |
| Alkermes, Inc. | 24 | $484 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $386 |
| Vanda Pharmaceuticals Inc. | 11 | $234 |
| Otsuka America Pharmaceutical, Inc. | 12 | $216 |
| Janssen Pharmaceuticals, Inc | 7 | $162 |
| AstraZeneca Pharmaceuticals LP | 5 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $136 |
| GlaxoSmithKline, LLC. | 4 | $75 |
| ABBVIE INC. | 3 | $57 |
Products named: INGREZZA, ARISTADA, CAPLYTA, REXULTI, FANAPT, INVEGA SUSTENNA, Kerendia, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
